OvaScience, a Cambridge, Mass.-based fertility company focused on the discovery, development and commercialization of novel treatments for infertility, has completed a $37m Series B financing.
The round was led by General Catalyst, with participation from existing investors Bessemer Venture Partners and Longwood Fund and new investors BBT Capital Management Advisors, LLC, Cycad Group, Hunt BioVentures, RA Capital and a large, global institutional investor, among others.
In conjunction with the financing, John Simon, managing director of General Catalyst, has joined OvaScience’s board of directors.
The company intends to use the funding to develop and commercialize its fertility treatment approaches based on the egg precursor cell discoveries of OvaScience co-founder Jonathan Tilly, Ph.D., director of the Vincent Center for Reproductive Biology, chief of research for Massachusetts General Hospital (MGH) Vincent Department of Obstetrics and Gynecology, and professor, Department of Obstetrics, Gynecology and Reproductive Biology at Harvard Medical School (HMS).
Led by CEO Michelle Dipp, M.D., Ph.D., OvaScience holds an exclusive license from MGH to an issued U.S. patent and various patent applications related to Dr. Tilly’s egg precursor cell discoveries.